The effect of direct antiviral therapy on hepatitis C virus related immune thrombocytopenia: a prospective controlled clinical trial

Background Hepatitis C related thrombocytopenia is multifactorial, one of these is the immunologically mediated viral suppression of bone marrow and immune system abnormalities resulting in immune thrombocytopenic purpura (ITP). Aim This study examined the impact of direct-acting antiviral therapy on platelet counts in patients with chronic hepatitis C who achieved sustained virologic response, and investigated the correlation between thrombocytopenia and antiviral treatment. Patients and methods Prospective study of 60 patients who diagnosed immune thrombocytopenic purpura with hepatitis C virus with matched sex and age who divided into two groups: group A treated with sofosbuvir/daclatasvir (SOF/DCV) and group B who taken ledipasvir/SOF (LDV/SOF) oral tablets and their PLT count assessed at baseline, 3, and 6 months after treatment. Results The mean PLT count increased 3 and 6 months after treatment in comparison between two groups, group A (who taken SOF/DCV), while in group B (who taken LDV/SOF) decrease 3 month after treatment and increase 6 month after treatment where the difference is not statistically significant between both but The difference is statistically significant between baseline, 3, and 6 month PLT count after treatment ( P =0.031). Conclusion Direct-acting antiviral therapy improved thrombocytopenia both during treatment and in long-term follow-up. the increase in PLT counts over time in both treatment groups was significant. The SOF/DCV group showed a consistent increase in PLT levels at both 3 and 6 months post-treatment. In contrast, the LDV/SOF group initially exhibited a decrease at 3 months but showed an increase at the 6-month mark. While these changes were statistically significant within a comparative analysis indicated no substantial difference in the degree of PLT count elevation between the two groups. Clinical trial no: ClinicalTrials.gov ID NCT03169348

Authors

Institutions

Publication Details

Journal
The Egyptian Journal of Haematology
Published
2025-04-01
DOI
https://doi.org/10.4103/ejh.ejh_112_24
Primary Topic
Hepatitis C virus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The effect of direct antiviral therapy on hepatitis C virus related immune thrombocytopenia: a prospective controlled clinical trial

Seham Mahrous, S. Khaled, Essam A.E. Sadik, Refaat F.A. Elal
The Egyptian Journal of Haematology
Hepatitis C virus research
article

The effect of direct antiviral therapy on hepatitis C virus related immune thrombocytopenia: a prospective controlled clinical trial

Seham Mahrous, S. Khaled, Essam A.E. Sadik, Refaat F.A. Elal
article en

Abstract

Background Hepatitis C related thrombocytopenia is multifactorial, one of these is the immunologically mediated viral suppression of bone marrow and immune system abnormalities resulting in immune thrombocytopenic purpura (ITP). Aim This study examined the impact of direct-acting antiviral therapy on platelet counts in patients with chronic hepatitis C who achieved sustained virologic response, and investigated the correlation between thrombocytopenia and antiviral treatment. Patients and methods Prospective study of 60 patients who diagnosed immune thrombocytopenic purpura with hepatitis C virus with matched sex and age who divided into two groups: group A treated with sofosbuvir/daclatasvir (SOF/DCV) and group B who taken ledipasvir/SOF (LDV/SOF) oral tablets and their PLT count assessed at baseline, 3, and 6 months after treatment. Results The mean PLT count increased 3 and 6 months after treatment in comparison between two groups, group A (who taken SOF/DCV), while in group B (who taken LDV/SOF) decrease 3 month after treatment and increase 6 month after treatment where the difference is not statistically significant between both but The difference is statistically significant between baseline, 3, and 6 month PLT count after treatment ( P =0.031). Conclusion Direct-acting antiviral therapy improved thrombocytopenia both during treatment and in long-term follow-up. the increase in PLT counts over time in both treatment groups was significant. The SOF/DCV group showed a consistent increase in PLT levels at both 3 and 6 months post-treatment. In contrast, the LDV/SOF group initially exhibited a decrease at 3 months but showed an increase at the 6-month mark. While these changes were statistically significant within a comparative analysis indicated no substantial difference in the degree of PLT count elevation between the two groups. Clinical trial no: ClinicalTrials.gov ID NCT03169348

The Egyptian Journal of HaematologyVol. 50(2)
Assiut University (EG)
Openalex Percentile: Top 70%
Hepatitis C virus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The effect of direct antiviral therapy on hepatitis C virus related immune thrombocytopenia: a prospective controlled clinical trial — Seham Mahrous, S. Khaled, et al. · The Egyptian Journal of Haematology (2025) | TGRS Research Map | TGRS